



 Cite this: *RSC Adv.*, 2025, 15, 688

# Cracking the code: the clinical and molecular impact of aminopyridines; a review (2019–2024)

 Tahira Khalid, Ayesha Malik, \* Nasir Rasool, Aqsa Kanwal, Hamna Nawaz and Iffat Almas

Aminopyridines belong to a class of compounds that are monoamino and diamino derivatives of pyridine. They work primarily by blocking voltage-gated potassium channels in a dose-dependent manner. Essential heterocycles used extensively in synthetic, natural products, and medicinal chemistry are aminopyridine and its derivatives. A vast array of biological and pharmacological effects can result from the interaction of aminopyridine rings with different enzymes and receptors, due to their unique structural properties. Aminopyridine research is continually growing, and there are now greater expectations for how it may aid in the treatment of numerous disorders. This review article will serve as an innovative platform for researchers investigating aminopyridine compounds, intending thoroughly to examine both traditional and novel synthesis strategies in addition to investigating the various biological characteristics displayed by these adaptable heterocycles. We attempt to provide valuable insights that will contribute to further progress in the synthesis and utilization of aminopyridines in various fields.

 Received 17th October 2024  
 Accepted 16th December 2024  
 DOI: 10.1039/d4ra07438f  
[rsc.li/rsc-advances](https://rsc.li/rsc-advances)

## 1 Introduction

N-heterocyclic complexes exhibit a huge spectrum of remarkable biological properties.<sup>1</sup> The nitrogen-bearing heterocycle pyridine in all of its similar forms is an important source of pharmaceuticals with therapeutic action in medicinal chemistry research. The Food and Drug Administration (FDA) has regularly authorized this privileged scaffold along with a long list of other pharmaceutical candidates. Due to its ease of parallelization and potential for chemical space testing, this moiety is gaining interest in a variety of disease scenarios.<sup>2,3</sup> Besides, it is a key solvent and reagent,<sup>4</sup> also essential to the advancement of drugs.<sup>5–7</sup> The majority of pyridine derivatives are playing a crucial role in HIV antiviral therapy,<sup>8</sup> as well as in hypnosis,<sup>9</sup> sedation,<sup>10</sup> bone calcium,<sup>11</sup> cholesterol,<sup>12</sup> and triglyceride regulation,<sup>13</sup> as antidiabetic,<sup>14</sup> antihistaminic,<sup>15</sup> antiulcerate,<sup>16</sup> anti-neoplastic,<sup>17</sup> and anticancer agents.<sup>18</sup> A versatile surface modification for immobilizing nanoparticles is poly vinyl pyridine **1**.<sup>19</sup> Niacin, or nicotinic acid **2**, is a vitamin B-3 and an essential component of food for humans.<sup>20</sup> Tryptophan is an amino acid that can be produced by both plants and animals.<sup>21</sup> Nicotine **3** is a stimulant that speeds up the messages from the brain to the body.<sup>22</sup> An alkaloid called anabasine **4**, containing piperidine and pyridine, is found in the stems and leaves of tobacco plants.<sup>23</sup> It is both chemically and structurally identical to nicotine, mostly used as an insecticide in industry.<sup>24</sup> Toxalbumin ricinine **5** is obtained from *Ricinus communis*, produces

castor beans.<sup>25</sup> Atazanavir **6** is used along with other medications to treat human immunodeficiency virus (HIV) infections.<sup>26</sup> Imatinib mesylate **7** is used for gastrointestinal stromal tumors.<sup>27</sup> Pyridoxal **8** is one of the regular forms available of vitamin B-6, for treating dietary shortages or imbalances (Fig. 1).<sup>28,29</sup>

Aminopyridine, a derivative of pyridine, first came to prominence through scientific studies in the mid-20th century.<sup>30</sup> 2-Aminopyridine (2-AP) **9** is a completely functionalized, low molecular weight moiety used in the synthesis of many different biological compounds,<sup>31</sup> being synthesized by a large number of pharmaceutical companies worldwide.<sup>32–36</sup> 2-AP functions as an ideal propellant in pulling these molecules in the direction of their pharmacological purposes.<sup>37</sup> The first aminopyridine to be applied in a therapeutic setting is 4-aminopyridine (4-AP) **10**.<sup>38</sup> That stimulates the release of acetylcholine and conceivably noradrenaline at nerve terminals by blocking potassium channels.<sup>39</sup> When the pharmacological characteristics were first reported in 1924, remarks were made about the drug's excitatory effects on the central nervous system and its vasopressor activity.<sup>40</sup> In the 1960s and 1970s, research began to reveal its potential therapeutic uses, particularly in neurology.

Amopyra **10**, also known as dalfampridine, is an aminopyridine that facilitates walking in multiple sclerosis (MS) patients.<sup>41</sup> This potassium channel blocker is used to treat neuromyelitis optica spectrum disorder (NMOSD) and MS in order to improve motor function.<sup>42</sup> Sulfasalazine **11**, as an Immunomodulator and Crizotinib **12** is a tyrosine kinase inhibitor of the anaplastic lymphoma kinase (ALK), receptor

Department of Chemistry, Government College University Faisalabad, Faisalabad 38000, Pakistan. E-mail: [ayesha.m726@gmail.com](mailto:ayesha.m726@gmail.com)






Fig. 1 Naturally occurring pyridine derivatives.

tyrosine enzyme (ROS1) and mesenchymal epithelial transition (MET) kinases.<sup>43</sup> Crizotinib is a more operative for initial treatment for patients with newly identified advanced ALK-positive non-small cell lung cancer (NSCLC) than the platinum-based double-agent chemotherapy.<sup>44</sup> Amifampridine **13** is a medication that belongs to the aminopyridine class.<sup>45</sup> A histamine antagonist  $H_1$  called tripeleennamine is used against coughs, colds, and hypersensitivity reactions.<sup>46</sup> Mepyramine **14** is an antihistamine that is used to treat allergy symptoms, hypersensitivity responses, and urticaria.<sup>47</sup> Urinary tract analgesic phenazopyridine **15**, also referred to as pyridium, is used to treat urinary tract irritation in the short term and its unpleasant side effects, as burning and pain during urination (Fig. 2).<sup>48</sup> Pyrilamine acts on the  $H_1$  receptor and is an antihistamine of the first generation.<sup>49</sup> Aminopyridines are expected to be extensively used in next-generation drugs that address a wide range of diseases, including cancer, heart disease, and neurological complications.<sup>50,51</sup>

Improvements in synthetic chemistry and drug delivery strategies will augment the medicinal potential of aminopyridines and pave the way for the development of more effective, targeted medications with reduced side effects and improved bioavailability.<sup>52,53</sup> Aminopyridines are becoming essential parts of customized therapy techniques, which use drugs based on a patient's genetic composition and the specifics of their condition, as personalized medicine continues to gain traction.<sup>54</sup> By using the unique properties of aminopyridines and state-of-the-art technology, upcoming drug development initiatives are well-positioned to open up new routes for treating unmet medical needs and improving patient outcomes.<sup>55</sup> A higher proportion of innovative aminopyridine-based therapeutic candidates is anticipated in the upcoming years. The latest developments in novel aminopyridine-based molecular frameworks and their distinct therapeutic significance, as documented over the previous years, are combined in this study. It draws attention to a trend toward the usage of






Fig. 2 FDA-approved aminopyridine-containing drugs.

aminopyridine-based compounds in therapeutic development and the subsequent rise of a number of strong and promising candidates against a variety of expanding diseases.

## 2 Pharmacology

### 2.1 Anti-bacterial and anti-inflammatory potential

Inflammation is a process stimulated against pathogen infections,<sup>56</sup> is regulated by several molecules having anti-inflammatory activities.<sup>57</sup> The continuous production of inflammatory agents can lead to tissue and DNA damage by stimulating cell proliferation to cancer.<sup>58</sup> A novel mononuclear copper complex  $[\text{Cu}(\text{C}_5\text{H}_6\text{N}_2)_4]\text{Br}_{2.2}(\text{C}_3\text{H}_7\text{NO})$  **17**, called Cu-4AP-Br was reported by the reaction of copper bromide **16** and 4-amino pyridine **10** hydrothermally in DMF solution. That shows remarkable antioxidant and antibacterial activities. For measuring its anti-inflammatory activity naproxen (NAP) **18** a known, effective anti-inflammatory drug was taken as reference. The inhibition of 5-lipoxygenase (5-LOX) activity of NAP and Cu-4AP-Br are shown in Table 1. The anti-inflammatory

activity of this pure molecule was 4.6 times higher than that of the synthetic material at a dose of  $25 \mu\text{g mL}^{-1}$ . The finding has shown that, at a test concentration of  $100 \mu\text{g mL}^{-1}$ , Cu-complex exhibited high anti-inflammatory activity ( $\text{IP} = 54.2 \pm 2.08\%$ ). The standards were provided as the mean  $\pm$  SD of three independent measures ( $n = 3$ ). Using Cu-4AP-Br and NAP as an optimistic regulator (Scheme 1).<sup>59</sup>


Antibiotics are the “magical shots” that fight bacteria, their discovery is regarded as a medical marvel. With the growing use, microorganisms have established antimicrobial resistance (AMR).<sup>60</sup> AMR refers to the potential of microorganisms to flourish in the middle of drugs designed to kill them. Antibiotics are a class of antimicrobials specially used to contest bacterial infections.<sup>61</sup> A novel and effective multicomponent one-pot technique for the preparation of derivatives of 2-amino-3-cyanopyridine from 3-dimethylamino phenylprop-2-en-1-one **19**, malononitrile **20** and substituted amines **21** was proposed. The synthesized molecules (**22a–d**) were examined, and based on their antimicrobial activity, compound **22c** showed the maximum antibacterial action specifically against *S. aureus* and *B. subtilis*, with MIC values of  $39 \pm 0.000 \mu\text{g mL}^{-1}$  (Scheme 2).<sup>62</sup>

Three novel zinc(II) complexes containing 4-aminopyridine (4-NH<sub>2</sub>py) were reported. These complexes,  $[\text{Zn}(4\text{-NH}_2\text{py})_2(\text{-NCS})_2]$ ,  $[\text{Zn}(4\text{-NH}_2\text{py})_2\text{Cl}_2]$  and  $[\text{Zn}(4\text{-NH}_2\text{py})_2(\text{NCS})\text{Cl}]$ , were synthesized from methyl zinc(III)chloride hydrate **23**, methanol compound with 4-AP **24** and thiocyanate derivative **25**. The antibacterial screening of every complex was assessed *in vitro* using two different bacteria, *Staphylococcus aureus* and *Escherichia coli*. According to the findings, **26** has the strongest antibacterial activity of all the others. This variation results from variations in the interactions that the anion ligands elicit (Scheme 3).<sup>63</sup>


Table 1 Anti-inflammatory activity of mononuclear copper complex and NAP at several concentrations

Compounds	Concentration ( $\mu\text{g mL}^{-1}$ )	Inhibition
NAP	2.5	$15.01 \pm 0.47$
	5	$31.64 \pm 0.82$
	25	$95.00 \pm 2.3$
Cu-complex	25	$20.51 \pm 0.7$
	50	$37.96 \pm 0.39$
	100	$54.20 \pm 2.08$






Scheme 1 Synthesis of mononuclear copper complex from copper bromide and 4-AP.



Scheme 2 Synthesis of 2-amino-3-cyanopyridine derivatives.

Al-Fakeh *et al.*, synthesized complexes by mentioned metal salts:  $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ ,  $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$ ,  $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$ ,  $\text{PdCl}_2$  and  $\text{CrCl}_3 \cdot 6\text{H}_2\text{O}$  with Schiff base 27 and 2-amino-4,6-dimethyl pyrimidine (ADMPY) 28, produced when benzaldehyde reacted with *p*-phenylenediamine and hydroxy-naphthaldehyde. The antioxidant and antibacterial activities of the complexes were investigated.

$\text{Cu}(\text{II})$  and  $\text{Pd}(\text{II})$  complexes exhibited extraordinary activity, cobalt and chromium complexes presented temperate antioxidant activity, when compared to the standard (ascorbic acid) while  $\text{Pd}(\text{II})$  and  $\text{Cu}(\text{II})$  complexes were best antibacterial agents using gentamycin as standard (Fig. 3).<sup>64</sup>

Scheme 3 Synthesis of complex  $[\text{Zn}(\text{4NH}_2\text{py})_2(\text{NCS})_2]$ .




Fig. 3 Structures of Schiff base ligand and ADMPY.

Tosylated 4-AP **30** created from **10** and **29** latter complexed with different metals and employed as antibacterial agents. Compared to the coordinated imine of the complexes, the free imine nitrogen in the ligands vibrated at a higher frequency. This implied that the metal ions were receiving lone pair electrons from the free azomethine nitrogen. The antibacterial properties of the ligand and its complexes were assessed using a range of microorganisms. The outcome showed that tosylated 4-aminopyridine's antibacterial activity was increased by complexing with Co(II), Fe(II), and Ni(II) ions (Scheme 4).<sup>65</sup>


Ilkimen *et al.*, reported two new salts (**32** and **35**) obtained from 2-methoxy-5-sulfamoylbenzoic acid (**31**) and 2-aminopyridine (**9**) or 2-amino-4methylpyridine (**33**) and their Cu(II) complexes. Levofloxacin, Vancomycin, Cefepime, and Fluconazole were the standard antibiotics. All moieties exhibited antibacterial property. The compounds with the highest activity are Cu (OAc)<sub>2</sub>·2H<sub>2</sub>O (31.25 μg mL<sup>-1</sup>) for *Candida albicans*, **32** (31.25 μg mL<sup>-1</sup>) for *Lactobacillus monocytogens*, all compounds (7.60 μg mL<sup>-1</sup>) for *Bacillus subtilis*, **9** (31.25 μg mL<sup>-1</sup>) for *Enterobacter coli*, Cu complex (15.60 μg mL<sup>-1</sup>) for *Staphylococcus aureus*. All antibacterial drugs were active against *L. monocytogens* (Scheme 5 and Table 2).<sup>66</sup>

## 2.2 Antitrypanosomal and anti-malarial agents

Antitrypanosomal therapy of revived diseases in immunosuppressed patients results in declined intensity of parasitemia.<sup>67</sup>


Human African trypanosomiasis (sleeping sickness) is a parasitic infection that leads to death.<sup>68</sup> A methoxyphenol derivative **37** was reported as priority antitrypanosomal and selective antiplasmodial agent as inhibitors of *Trypanosoma brucei*. One of the compounds in the collection with promising drug-like properties produced was methylsulfonyl bipyridine amine **38** is undergoing clinical testing to treat malaria. With a view on *in vivo* mouse testing, they proposed an *o*-disubstituted phenyl B-ring to optimize the equilibrium between antitrypanosomal activity, solubility, and metabolic stability of this group. This was accomplished by joining molecules with an extra ring nitrogen atom on the C-ring of a *p*-cyclic amide with an *o*-disubstituted B-ring pattern (Fig. 4).<sup>69</sup>

Oliveira *et al.*, examined the effects of novel aminopyridine derivatives complexed with Cu<sup>2+</sup> against *T. cruzi* trypanostigote forms: *cis*-aquadichloro pyridinemethanamo copper (**39a**) and its glycosylated ligand, *cis*-dichloro (glucopyranosyloxy) phenyl methyl pyridinemethanamo copper (**39b**). These metalodrugs pre-treated trypanostigotes inhibiting the association index with LLC-MK2 cells. When tested on mammalian cells, both complexes shown minimal toxicity (CC<sub>50</sub> >100 μM). When tested on intracellular amastigotes, the IC<sub>50</sub> values were found to be 14.4 μM for compound **39a** and 27.1 μM for complex **39b**. Results determined the potential of these aminopyridines complexed with Cu<sup>2+</sup> as promising aspirants for additional antitrypanosomal drug development (Fig. 5).<sup>70</sup>



Scheme 4 Synthesis of monotosylated 4-AP.





Scheme 5 Synthesis of methoxy-sulfamoylbenzoate and amino-methylpyridinium salts and their copper metal complexes.

Table 2 MIC results of the synthesized salts and their metal complexes with standards ( $\mu\text{g mL}^{-1}$ )

Molecules	<i>C. albicans</i>	<i>L. monocytogens</i>	<i>B. subtilis</i>	<i>S. aureus</i>	<i>E. coli</i>
32	62.50	62.50	62.50	62.50	62.50
35	62.50	62.50	125.00	62.50	125.00
36a	62.50	62.50	125.00	125.00	125.00
36b	62.50	31.25	62.50	62.50	62.50
Vancomycin	—	125	250	62.50	31.25
Levofloxacin	—	31.25	62.50	31.25	31.25
Cefepime	—	31.25	62.50	62.50	62.50
Fluconazole	62.50	—	—	—	—

### 2.3 Anti-multiple sclerosis

The autoimmune disease MS is the primary cause of non-traumatic neurological illness in adults.<sup>71</sup> MS is a global problem, and is very predominant.<sup>72</sup> Yet there is no cure for multiple sclerosis. Treatment usually emphasizes on speedy recovery from attacks, reduced radiographic and clinical relapses, reducing the progression of the disease.<sup>73</sup> It has been proved that 4-AP that is accepted for the MS. As possible options for positron emission tomography (PET) imaging, they looked into four new 4-AP derivatives. Three out of the four molecules were potent to block the voltage-gated potassium channels KV1. In particular, it was discovered that 3-methyl-4-aminopyridine (3Me4-AP) was roughly 7 times more effective than 4-AP (10)






Fig. 4 Structures of reported compounds methoxyphenol **37** and methyl sulfonyl bipyridine amine **38**.

and 3-fluoromethyl-4-aminopyridine (3F4-AP) (**41a**); 3-methyl-4-aminopyridine (3Me4-AP), 3-methoxy-4-aminopyridine (3MeO<sub>4</sub>AP) (**41b** and **41c**) was about 3–4 times less potent than 4-AP; and 2-trifluoromethyl-4-aminopyridine (2CF<sub>3</sub>4-AP) (**41d**, **41e**) was approximately 60-fold less active. Their findings implied that these new compounds has found use in imaging and therapy (Table 3).<sup>74</sup>

Aydoğmuş *et al.*, established the involvement of K<sup>+</sup> channels in the cell cycle by using 4-AP in conjunction with paclitaxel (PTX) (**42**) in MCF-7 and MDA MB-231 cell lines. To estimate viability, trypan blue was utilized. For understanding the mechanism, intracellular K<sup>+</sup> concentration, intracellular Ca<sup>2+</sup> concentration, and transmembrane potential measurements were made with fluorescent dyes. According to cell cycle analysis, 4-AP therapy made the MCF-7 and MDA MB-231 cell lines go into G1 arrest. PTX caused G1 stop in MCF-7 cells and S phase in other cells. Combination therapy caused S phase arrest

in MCF-7 cells and both G2/M and S phase arrest in MDA MB-231 cells. After every treatment, the intracellular K<sup>+</sup> content increased in both cell lines. The Ca<sup>2+</sup> concentration significantly improved after combo conduct. This work indicated that the grouping of 4AP and PTX was a viable substitute, taking into account the findings for Ca<sup>2+</sup>, K<sup>+</sup>, and membrane potential (Fig. 6).<sup>75</sup>

Table 3 IC<sub>50</sub> of 4-AP derivatives and confidence interval. *N* is the number of times each was tested

Drug	IC <sub>50</sub> (μM)	95% C.I. (μM)	<i>N</i>
<b>10</b>	293	258–328	6
<b>41a</b>	244	185–303	5
<b>41b</b>	40	36–43	4
<b>41c</b>	807	762–853	4
<b>41d</b>	1061	914–1209	6
<b>41e</b>	12 776	8838–16 715	4




Fig. 5 Structures of the metal-based amino pyridines *cis*-aquadichloro pyridinemethamino copper (**39a**) and *cis*-dichloro tetra-*O*-acetyl-β-*D*-glucopyranosyloxy phenyl methyl pyridinemethamino copper (**39b**).






Fig. 6 Structure for paclitaxel.

4-AP is a selective voltage blocker channel used for multiple sclerosis patients. The investigation was divided into two phases: after 4-AP underwent H/D exchange, serum monoamine oxidase activity was measured by applying both deuterated and non-deuterated 4-AP to MS patients' serum. There were 120 subjects in total for the trial, split into two groups of 60: MS sufferers and control. Patients' monoamine oxidase (MAO) activity was considerably ( $P < 0.01$ ) higher than the control groups. When 4-AP was present, there was a significant ( $P < 0.01$ ) drop in MAO activity, and this drop was further pronounced when deuterated 4-AP was present. In conclusion, 4-AP has an inhibitory effect on MAO activity, and this effect was enhanced when deuterium was used in place of hydrogen (Scheme 6).<sup>76</sup>

4-AP was reported as symptomatic treatment in several neurologic illnesses because it is an antagonist of Kv channels.





Fig. 7 Structure of fampridine/4-AP (10) a formulation against MS.

4-AP is linked to MS patients for improved motor function, improved vision, and reduced fatigue. For the characteristic treatment of walking deficiency in MS, its sustained release formulation fampridine **10** has received approval. The enhancement of conduction along demyelinated axons was attributed to the blockage of axonal Kv channels, which accounted for positive effects. Nonetheless, a growing amount of data indicated that fampridine has offered benefits in addition to its symptomatic mechanism of action (Fig. 7).<sup>77</sup>


#### 2.4 Against metabolic enzymes

Türker *et al.*, studied the enzyme inhibition properties of the Pd-based complexes having both N-heterocyclic carbene (NHC) ligands and 2-AP. The 3-cyanobenzyl group in the NHC ligand of these complexes has inhibitory effects on a few metabolic enzymes, including xanthine oxidase (XO) and carbonic anhydrase (hCA). For hCA I, hCA II, hCA, plus XO the  $IC_{50}$  ranges were found to be 0.325–0.707, 0.238–0.636, and 0.576–1.693  $\mu\text{M}$ , respectively. Pd(II)-NHC compounds containing 2-AP might be effective hCA and XO inhibitors. The novel Pd-based



Scheme 6 Acid–base equilibrium of 4-AP analogues.





Scheme 7 (NHC)PdBr<sub>2</sub>(2-aminopyridine) complexes: synthesis and structures for their derivatives.

compounds **44a–44f** comprised a combination of NHC ligand **42** and 2-AP **9**. PdBr<sub>2</sub> (pyridine) complexes from the starting material NHC have a weak attachment between the pyridine ligand and the palladium centre. Their findings pointed to the implementation of effective medicine for XO (Scheme 7 and Table 4).<sup>78</sup>

Aminopyridine containing thiourea derivatives have developed as a vital class of bioactive pharmacophores in the realm of medicinal chemistry.<sup>79</sup> Rizvi *et al.*, reported the synthesis of aminopyridine thiourea derivatives (**47a–47p**) as a powerful, non-competitive inhibitors of  $\alpha$ -glucosidase enzyme with a half-

maximal inhibitory concentration ranges from  $24.62 \pm 0.94$  to  $142.18 \pm 2.63 \mu\text{M}$  *in vitro* assays (Table 5). Here, compound **47e**, **47g**, **47h**, **47n** and **47o** exhibited most potent activity (Table 6). Results were supported by computational studies that showed important interactions between enzymes through hydrophobic and  $\pi$ - $\pi$  assembling forces. Molecular docking and density functional theory were used in kinetic experiments to examine the type of contacts, free energy, and manner of inhibition (Scheme 8).<sup>51,80</sup>

A novel set of kojic acid derivatives conjugated to amino pyridine intended to investigate its tyrosinase-inhibiting potential was presented. Each derivative showed a distinct inhibitory potency when tested against tyrosinase in comparison to kojic acid, which served as the positive control. Every derivative's antioxidant activity was computed. Compound (**48**) binds to the enzyme in an uncompetitive manner, according to the kinetics of the most active agent. As a result of their strong binding affinity and notable interactions with the tyrosinase enzyme to target the melanogenesis pathway, the analysis suggests that they could be effective future candidates to regulate hyperpigmentation (Fig. 8).<sup>81</sup>

Table 4 The IC<sub>50</sub> values of the NHC PdBr<sub>2</sub> 2AP compounds **44a–44f** on HCA (I) and XO

Compound	XO ( $\mu\text{M}$ )	hCAI ( $\mu\text{M}$ )	hCAI ( $\mu\text{M}$ )
<b>44a</b>	$1.08 \pm 0.04$	$0.47 \pm 0.03$	$0.54 \pm 0.04$
<b>44b</b>	$0.66 \pm 0.01$	$0.35 \pm 0.05$	$0.46 \pm 0.04$
<b>44c</b>	$1.69 \pm 0.06$	$0.71 \pm 0.04$	$0.64 \pm 0.05$
<b>44d</b>	$0.65 \pm 0.02$	$0.41 \pm 0.03$	$0.34 \pm 0.03$
<b>44e</b>	$0.58 \pm 0.02$	$0.41 \pm 0.04$	$0.24 \pm 0.03$
<b>44f</b>	$0.59 \pm 0.05$	$0.33 \pm 0.02$	$0.32 \pm 0.03$



Table 5 The IC<sub>50</sub> values of the 1-phenyl-3-(5-(trifluoromethyl)pyridin-2-yl)thiourea derivatives against  $\alpha$ -glucosidase

Compound	$\alpha$ -Glucosidase inhibition IC <sub>50</sub> $\pm$ SEM ( $\mu$ M)	Compounds	$\alpha$ -Glucosidase inhibition IC <sub>50</sub> $\pm$ SEM ( $\mu$ M)
47a	92.1 $\pm$ 3.07	47i	56.81 $\pm$ 2.41
47b	—	47j	97.91 $\pm$ 0.68
47c	81.31 $\pm$ 0.86	47k	142.18 $\pm$ 2.63
47d	59.76 $\pm$ 1.36	47l	121.61 $\pm$ 1.36
47e	24.62 $\pm$ 0.94	47m	68.91 $\pm$ 1.72
47f	63.21 $\pm$ 0.96	47n	28.63 $\pm$ 2.04
47g	41.87 $\pm$ 1.16	47o	38.85 $\pm$ 2.17
47h	39.86 $\pm$ 1.73	47p	109.31 $\pm$ 1.89
Acarbose	875.85 $\pm$ 2.03		

Table 6 Results of kinetic inhibition studies of most potent compounds (47e, 47g, 47h, 47n, 47o)

Compounds	K <sub>i</sub> $\pm$ SEM ( $\mu$ M)	Type of inhibition
47e	19.96 $\pm$ 0.0318	Non-competitive
47g	36.17 $\pm$ 0.0112	Non-competitive
47h	34.21 $\pm$ 0.0036	Non-competitive
47n	47.23 $\pm$ 0.0076	Non-competitive
47o	24.97 $\pm$ 0.0231	Non-competitive

## 2.5 Inhibitor of Janus kinase 2 gene

Janus kinase-2 (JAK2) is a non-receptor tyrosine kinase that works as the cytokine receptor's intracellular signalling effector, modulating the effects of growth hormone, leptin, erythropoietin, and interferon.<sup>82</sup> 3-Methoxypyridine-2-amine (53) reported as the encouraging inhibitor of JAK2 which exhibits great inhibitory effect against myeloproliferative neoplasms IC<sub>50</sub> = 6 nM and rheumatoid arthritis and 3 nM, and selectivity for JAK 2 and displayed effective antiproliferative activities against human erythroleukemia cell line human erythroleukemia cells (HEL). Its more effective versions as 54a and 54b. Furthermore, 54a reduced the signs and symptoms in rats with the collagen induced arthritis (CIA model). The freshly synthesized s compounds were screened at 50  $\mu$ M to see if they could bind to JAK2 (Scheme 9 and Table 7).<sup>83</sup>

Munir *et al.*, examined how 2-AP compounds bind when used as JAK2 inhibitors. Credible 3D-quantitative structure-activity relationship (QSAR) models were created and validation showed that the models could be used to predict the bioactivities of JAK2 inhibitors. One hundred novel JAK2 inhibitors with increased potency were computationally developed using the structural criteria supplied by the model's contour maps. A 100 ns molecular dynamic (MD) simulation was performed on the chosen complexes, which helped to forward the investigation of the binding interactions. Positive outcomes were found for internal library compound in the initial *in silico* study. The conclusions provided insightful advice for the development of powerful and novel JAK2 inhibitors (Fig. 9).<sup>84</sup>

## 2.6 Anti-neurodegenerative


Neurodegenerative disorders are characterized by loss of selectively vulnerable populations of neurons.<sup>85</sup> 4-AP was

reported as a potential treatment for trigger point injection (TPI) using regular mouse models with functional outcomes including sensory indices, sciatic-functional-index and electro diagnostics. 4-AP has also improved nerve conduction velocity recovery, promoted remyelination, extended the quantity of axonal area after injury, and enabled rapid differentiation between nerve lesions. Accordingly, 4-AP provided a novel prospective therapy to enhance healing and remyelination in cases of significant peripheral nerve injury in addition to a special technique for detecting lesions where the therapy was most likely to be successful.<sup>86</sup>

The beneficial effects of 4-AP were validated, in promoting remyelination and the restoration of motor function, nerve conduction velocity, and sciatic nerve crush injury in mice. The sciatic nerve crush injury and no-injury groups of mice were divided into groups, and observed with or without 4-AP and saline treatment evaluating the skeletal muscle's morphological, functional, and transcriptional characteristics. 4-AP markedly decreased muscle atrophy while increasing muscle thickness and contractile force, in addition to enhance *in vivo* function. The results offered fresh perspectives on 4AP's possible therapeutic benefits in contradiction of nerve injury-induced muscle atrophy and dysfunction.<sup>87</sup>

Vasu *et al.*, reported Blood-Brain Barrier penetration (BBB) of neuronal nitric oxide synthase (nNOS) inhibitors toward novel medications for neurodegenerative illnesses. The crystal structures of the majority of newly developed complexes complexed to different nitric oxide synthase isoforms were examined in addition to the inhibitor efficacy and selectivity. An efflux ratio of 0.8 in the Caco-2 bidirectional experiment indicated a considerably low substrate liability for P-glycoprotein and cancer resistant proteins, while a novel derivative (56) showed good potency ( $K < 30$  nM) in nNOS inhibition. It was detrimental to increase their lipophilicity in order to increase permeability. As a result, they looked into the lead chemical 56's metabolic stability in human liver microsomes (HLM) and mouse liver microsomes (MLM). For HLM and MLM, terfenadine and imipramine employed as controls respectively. The findings showed that 56, with a half-life ( $t^{1/2}$ ) of 29 minutes, exhibited moderate stability in MLM. In contrast, both compounds showed excellent stability in HLM, with half-lives longer than 60 minutes (Fig. 10 and Table 8).<sup>88</sup>





Scheme 8 Synthesis of 1-phenyl-3-(5-(trifluoromethyl)pyridin-2-yl)thiourea derivatives.




Fig. 8 Structure of methyl-pyran-4-one (48).


### 2.7 Anti-tranquilizing and antidepressant activity


Antidepressants are common prescriptions that help to treat depression and other conditions like anxiety<sup>89</sup> and the

tranquilizers are used to treat anxiety and insomnia.<sup>90</sup> New compound arylmethylamino phenylpyridine for a tranquilizing activity was reported.<sup>91</sup> Numerous derivatives with greater neurotropic activity compared to drugs Mexidol and Amitriptyline were recognized. In order to create new aminopyridone derivatives and to check them for nootropic activity, the synthesis of compounds **61** based on amino-methyl-phenylpyridine was performed. Pyridones **61a-c** were obtained in higher yields by reacting pyridine-2-one **59** with a number of aldehydes by reduction of imines **60** with sodium borohydride in 2-propanol at room temperature (Scheme 10 and Fig. 11).<sup>92</sup>

### 2.8 Anti-HIV

Human immunodeficiency virus, also called HIV damages the immune system so that the body is unable to combat disease. If





Scheme 9 Synthesis of 3-methoxypyridine-2-amine derivatives.

Table 7 The activity profiles of (54a), (54b) and ruxolitinib against JAK2 and their antiproliferative activity

Compound	Against JAK2 (IC <sub>50</sub> μM <sup>-1</sup> )	Antiproliferative (IC <sub>50</sub> μM <sup>-1</sup> )
54a	0.092 ± 0.007	15.024 ± 0.032
54b	0.572 ± 0.020	4.914 ± 0.056
Ruxolitinib	0.006 ± 0.0001	7.639 ± 0.363

HIV isn't treated, fails the immune system enough to become acquired immunodeficiency syndrome (AIDS).<sup>93</sup> 3-aminopyridine derivatives, on basis of the analogous chloroacetamide and condensed 1*H*-pyrido [2,3-*b*] [1,4] oxazine-2(3*H*)-one prepared by acylation reaction with chloroacetyl chloride. 3-Aminopyridine-2(1*H*)-one was reacted with several isothiocyanates to get thioureide derivatives. A cyclization of the

derivative of carbamothioyl methacrylamide into substituted 1,3-thiazine was demonstrated. The biotesting phase of thio-urea derivative 62 was conducted to determine its mode of inhibition of specific transcriptase types and its potential as an anti-HIV agent. 3-aminopyridine-2(1*H*)-one, acylates efficiently in CH<sub>2</sub>Cl<sub>2</sub> in pyridine to form the chloroacetamide in a good yield. Replacing CH<sub>2</sub>Cl<sub>2</sub> with DMF and an increase in temperature up to 80–100 °C lead to the cyclization of the intermediate 63 to 65 (Scheme 11).<sup>94</sup>

## 2.9 Muscular and neuronal activity

Govindappa *et al.*, discussed strategies to improve the possible therapeutic outcome of 4-AP in PNI-induced bone loss and muscle repair. The adult male mice's right sciatic nerve, as well as the femoral and sciatic nerves innervating it, were crushed.






Fig. 9 Structures of compound 3-methoxy-pyridine-2-amine (54a), (54b) and ruxolitinib.

Animals that had surgery were given 4-AP and regular saline. They discovered that 4-AP completely corrected trauma-induced alterations in muscle fibre type composition and greatly improved muscle morphology, cross-sectional area, and minimum ferret diameter from post-injury day 7. It also dramatically increased SFI, VFT, and hind limb paw grip strength. When compared to the saline group, the 4-AP-induced muscular effects were also linked to a much higher quantity of proliferating cells (Ki67+) and regenerating stem cells (Pax7+).<sup>95</sup>

Work on the use of thermogelling polymers to create a new local delivery system for 4-AP was reported. A thermosensitive formulation of a block copolymer (Poly-Lactic-Glycolic-Acid-Poly-Ethylene-Glycol (PLGA-PEG)) **68** was improved. Following a spinal nerve crush injury showed a marked improvement in motor and sensory functional recovery using a single dose of (4-AP)-PLGA-PEG. Additionally, immunohistochemistry analyses of injured nerves treated with (4-AP)-PLGA-PEG showed elevated

neurofilament heavy expression. Using cerebral spheroids created from human induced pluripotent stem cells (iPSCs), examined 4AP effects on neuronal activity and related neurogenesis. They reported that 4-AP increases neuronal activity also enhanced the number of neurons and glial cells. These findings indicated that iPSC-derived brain spheroids were desirable for investigating several aspects of activity-induced neurogenesis (Scheme 12).<sup>96</sup>

Table 8 Metabolic constancy of nNOS inhibitors in mouse and HLM

Compounds	Half-life ( $t^{1/2}$ , min) MLM	HLM
56	29	>60
Terfenadine		15
Imipramine	9	





Fig. 10 Structure of human neuronal NOS inhibitors having a 2-AP scaffold and the drugs.





Scheme 10 Synthesis of 3-(arylmethylamino) pyridones derivatives 61a–c.

Moreover, it was demonstrated that both dopamine depletion in the striatum and methyl-phenyl-tetrahydropyridine (MPTP) induced neuronal death in the sensory neurons were prevented by 4-AP. The rotarod test and open field test behaviour index verified that 4-AP reduced the motor impairments brought on by MPTP 69. Additionally, they demonstrated that the MPTP-induced rise in malonaldehyde (MDA) and drop in superoxide dismutase (SOD) levels could be considerably

mitigated by 4AP therapy. Furthermore, 4-AP reversed the effects of MPTP-induced neurotoxicity on dopaminergic neurons by substantially reducing B-cell lymphoma-2 expression and increasing caspase-3 activation. According to these findings, 4-AP reduces oxidative stress and apoptosis in order to protect dopaminergic neurons against MPTP. This is a therapeutic agent for treatment of Parkinson disease (Fig. 12).<sup>97</sup>






Fig. 11 Graph presenting comparison of arylmethylamino methyl phenylpyridine and comparator drugs.



Scheme 11 Synthesis of 1*H*-pyrido [2,3-*b*] [1,4] oxazin-2(3*H*)-one 65.

Scheme 12 Synthesis of PGLA-PEG polymer.







Fig. 12 Structure of MPTP.

Yang Sun *et al.*, discussed a new Kv1 channel tracer called [ $^{11}\text{C}$ ] methyl-4-aminopyridine ([ $^{11}\text{C}$ ]3Me4-AP) **75**. Through the effective Stille cross-coupling of a stannyl precursor with a free amino group mediated by Pd (0)-Cu(I), [ $^{11}\text{C}$ ]3Me4-AP was produced. In rats and nonhuman primates, evaluation of [ $^{11}\text{C}$ ] 3Me4-AP's imaging properties revealed that it had slow kinetics and a moderate level of brain permeability. A one-tissue section model precisely simulated the regional brain time-activity curves, and further testing in monkeys shown that the tracer is metabolically stable. [ $^{11}\text{C}$ ] methoxy-4-aminopyridine ([ $^{11}\text{C}$ ] 3MeO4-AP) **73** and [ $^{18}\text{F}$ ], ([ $^{18}\text{F}$ ]3F4-AP) **71**, two similar tracers, are less common than [ $^{11}\text{C}$ ] with slower kinetics and lower initial brain absorption. That indicated reduced permeability to the blood-brain barrier. 3Me4-AP (**75**) suggests a higher binding affinity that is in line with *in vitro* studies. Conversely, the tracer's less desirable characteristics were brought about by the gentle kinetics and high binding affinity. That indicated reduced permeability to the blood-brain barrier and slower kinetics (Scheme 13).<sup>98</sup>

## 2.10 Anticancer

Cancer is a class of disorders that can begin in any bodily tissue when aberrant cells proliferate out of control and spread to



Scheme 13 Synthesis of novel tracer for potassium Kv1 channels $^{11}\text{C}$  3Me4-AP (**75**).



other bodily regions.<sup>99,100</sup> Cancer is the leading causes of premature deaths globally.<sup>101,102</sup> A new synthesized pyridine methyl naphthalene for cancer treatment against human lung (H-460) and breast (MCF-7) cell lines was reported. The ligand **L** (**76**) was prepared by reacting hydroxy-naphthaldehyde with 2-AP. The antidepressant activity was evaluated by raised plus maze model using Diazepam as reference. An  $\text{IC}_{50}$  of  $23.99\ \mu\text{g}\ \text{mL}^{-1}$  against H-460 and  $31.68\ \mu\text{g}\ \text{mL}^{-1}$  against MCF-7, respectively, demonstrated 89.20% anticancer activity at the maximal tested dose ( $500\ \mu\text{g}\ \text{mL}^{-1}$ ) and recommended the compound's potential for application as an anticancer agent as well (Scheme 14).<sup>103</sup>

Naz *et al.*, reported the synthesis of amino acid conjugates of aminopyridine as potential anticancer agents. The parent (A2780) and cisplatin-resistant (A2780CISR) ovarian cancer cell lines were used to assess the cytotoxic activity. In contrast to parent cells, the results indicated that **82** and **83** demonstrated encouraging suppression in cisplatin-resistant cell lines in terms of both resistance factor and  $\text{IC}_{50}$  values (Table 7). Moreover, with  $\text{IC}_{50}$  values of  $31.45\ \mu\text{M}$  and  $15.41\ \mu\text{M}$  in the case of the parent and resistant cell lines, respectively, **83** was found to be the most active chemical. Docking experiments confirmed that compounds **82** and **83** exhibited significant binding affinities with several signalling cascade protein targets. In cisplatin-resistant cell lines, the anticancer properties of compounds **82**, and **83** indicated that these ligands might serve as lead compounds for enhanced novel anticancer medications (Scheme 15 and Table 9).<sup>104</sup>


An innovative selective CDK8 inhibitor against colon cancer discovered was reported *in vivo*. To be more precise, a number of novel 2AP derivatives were produced, and assessed using the structural details of the sorafenib-bound CDK8 structure. Of them, compound urea derivative **84** exhibited good selectivity and substantial inhibitory action against CDK8 with an  $\text{IC}_{50}$  value of  $46\ \text{nM}$ . Additionally, there appeared a relationship between biotinylated-**81** and endogenous or overexpressed CDK8. This substance demonstrated antiproliferation efficacy on colon cancer cell lines with elevated levels of CDK8 expression, inhibited WNT/ $\beta$ -catenin activation and TCF family transcriptional activity, and caused G1 phase arrest in HCT-116 cells. Furthermore, this substance exhibited strong efficacy against HCT-116 cells that were resistant to Sorafenib (a potent cancer drug). Additionally, it demonstrated appropriate pharmacokinetic and minimal toxicity (Fig. 13).<sup>105</sup>

Metal complexes related with organic ligands have gained much interest due to their structural variety and wide applications.<sup>106</sup> Aminopyridines possess anticancerous potential through initiating ribonucleotide reductase, responsible for allowing them to target numerous cancerous diseases mainly gynecologic cancer.<sup>107</sup> Mhadhbi *et al.*, published the organic and inorganic fusion complex  $(2\text{-HAP})_2[\text{CoBr}_4]$ , where 2-HAP = 2-protonated aminopyridinium cation, as explained by a number of physicochemical techniques. Three phase transitions at  $T_1 = 61.9\ ^\circ\text{C}$ ,  $T_2 = 107.6\ ^\circ\text{C}$ , and  $T_3 = 172\ ^\circ\text{C}$  were revealed by the differential scanning calorimetric method. Malignant Mat-Ly-Lu and Walker 256/B cell lines were used to assess the anticancer effects and dose response effect in Table 8.




Scheme 14 Synthesis of Schiff base ligand L 1-((pyridin-2-ylimino)methyl)naphthalene-2-ol (**77**).

Scheme 15 Synthesis of aminopyridine containing amino acid conjugates as potential anticancer agents.



**Table 9** Anticancer potential of amino pyridine derivatives against A2780 (parent) and A2780CISR (cisplatin-resistant) ovarian cancer cell lines, expressed as IC<sub>50</sub> values and compared to cisplatin, the standard drug

Tested compounds	IC <sub>50</sub> (μM)		Resistance factor
	A2780*	A2780CISR**	
<b>82</b>	39.14 ± 1.79	51.21 ± 1.65	1.31
<b>83</b>	31.45 ± 0.02	15.41 ± 1.52	0.49
Cisplatin	0.61 ± 0.06	16.43 ± 1.45	26.93



**Fig. 13** Structure of reported AP derivative.

Using molecular docking, the antiviral properties of the organic portion of these hybrid compounds were investigated; notably, the binding projected energy was  $-4.0$  vs.  $-5.3$  kcal mol<sup>-1</sup> for chloroquine that was used as reference. The drug-likeness,


pharmacokinetics, molecular binding and chemo-preventive assays displayed that (2-HAMP)<sub>2</sub>[CoBr<sub>4</sub>] has encouraging biological potentials (Table 10).<sup>108</sup>

Luan *et al.*, examined the anticancer properties of compact graphene oxide (HRGO) and gold nanomaterial (AuNM)-based (HRGO/Au@AP) nanocomposite for ovarian cancer, as well as the nanomaterials' ability to induce apoptosis and human ovarian cancer cell lines (SKOV3 and A2780). In order to increase the sample's solubility and bioavailability, HRGO was functionalized with 1AP as a potential stabilizing agent. Apoptosis assays, oxygen species measurements on SKOV3 and A2780 cells, and the findings of an anticancer investigation demonstrated a better capacity to trigger apoptosis. According to this study, HRGO/Au@AP may promote apoptosis in human ovarian cancer cells.<sup>109</sup>

Liu *et al.*, examined new 2-AP derivatives produced and put through biological testing after being logically generated using molecular simulation. With an IC<sub>50</sub> value of 42.3 nM, the chosen spiro derivative C01 demonstrated exceptional activity against CD74-ROS1<sup>G2032R</sup> cells, 30 times more effective than Crizotinib (cancer growth blocker) (**85**). Furthermore, C01 (**86**) exhibited a 10-fold higher potency than Crizotinib and potently suppressed enzymatic activity against clinically resistant ALK<sup>G1202R</sup>. The susceptibility of C01 to drug-resistant mutant was explained by molecular dynamic, which showed that adding the spiro group might lessen the steric hindrance with huge side chain (arginine) in solvent region of ROS1<sup>G2032R</sup>. These findings pointed to a future direction for the development of ROS1/ALK dual inhibitors resistant to Crizotinib (Scheme 16).<sup>110,111</sup>


**Table 10** Anticancer effect of (2-HAMP)<sub>2</sub>[CoBr<sub>4</sub>] on malignant Mat-Ly-Lu (prostate cells) and Walker 256/B mammary gland carcinoma cells

Dose-dependent concentration (μg mL <sup>-1</sup> )	Proliferative inhibition (%)	
	Malignant Mat-Ly-Lu	Walker 256/B mammary glands
(2-HAMP) <sub>2</sub> [CoBr <sub>4</sub> ]		
CTRL	0.9	1.2
H <sub>2</sub> O <sub>2</sub>	99.2	98.8
10	8.17	17.2
20	18.8	25.4
30	29.74	36.6
50	53.51	62.5



**Scheme 16** Novel 2-aminopyridine derivatives Crizotinib (**82**) and C01 (**83**) which was about 30 times more potent than Crizotinib.





Scheme 17 Synthesis of 2-amino-pyridine-3-carbonitrile derivatives effective against anti-tuberculosis.

Table 11 Effects of chronic intermittent hypoxia CIH on body weight and mortality rate

Entries	CTL	CIH	Statistics
Initial body weight	155.6 ± 1.7g	154.2 ± 5.2g	$P = 0.24$ (MW = 204.5, df = 20)
Final body weight	273.9 ± 4.1g	258 ± 3.0g	$P < 0.001$ (MW = 96, df = 20)
Mortality rate	0% (0/8 animals)	16% (2/14 animals)	$P < 0.001$

### 2.11 Anti-tuberculosis

Tuberculosis (TB) is an infection that affects lungs. Caused by bacteria that spreads by air when infected people sneeze, cough or spit. A range of recently synthesized fluorinated chalcones **86**, chosen them *in vitro* antitubercular action, along with its 2AP 3-carbonitrile and 2-amino 3-carbonitrile derivatives was revealed. Out of all synthesized compounds, compound **87b** bearing indolyl scaffolds (MIC = 8 μM) had the highest potency. Its potency is comparable to that of broad-spectrum antibiotics such as streptomycin and ciprofloxacin, and it is three times more effective than pyrazinamide. When docking against thymidylate kinase, molecule **87b**, which proved to be the most effective, displayed a binding energy of  $-9.67 \text{ kcal mol}^{-1}$ , which was compared with its *in vitro* MIC value ( $\sim 8 \text{ μM}$ ). The findings suggested that compound **82q**, which is the most effective, exhibits selective activity against the H37Rv strain of *Mycobacterium TB*. Therefore, it is safe to process the molecule further in order to create a new antitubercular drug (Scheme 17).<sup>112</sup>

### 2.12 Anti-epileptic

Epilepsy is most common serious brain disorder, affecting over 70 million people worldwide.<sup>113</sup> Salazar *et al.*, evaluated the effects of chronic intermittent hypoxia (CIH) on spread activity of the hippocampus *in vitro*, as well as whether these changes persisted or disappeared with normal oxygenation. According to the findings, giving adult rats CIH for 21 days magnifies 4AP-induced epileptiform activity *in vitro* and raises gamma-band hippocampal network activity. According to their research, CIH-induced changes in the hippocampal network and an increase in seizure was spontaneously reversed. This suggested that surgery or continuous positive airway pressure (CPAP), against obstructive sleep apnea (OSA) in epileptic patients, was beneficial for seizure control (Table 11).<sup>114</sup>

Debilitating diseases known as epileptic and developmental encephalopathies, which were characterized by seizures, intellectual impairment, and additional neuropsychiatric symptoms were reported. They demonstrated how the K<sup>+</sup> channel blocker 4-aminopyridine has reduced current amplitudes in KCNA2-encephalopathy and increased transfected neuron firing rate








Fig. 14 Structural profiles for 4-AP.

to counteract gain-of-function deficiencies brought on by changes in the KV1.2 subunits *in vitro*. Except for two who continued to have induced seizures, all six of the patients who had daily absence, myoclonic, or atonic seizures ceased to have seizures. Six people with generalized tonic-clonic seizures displayed no change at all, one deterioration, and three clear improvements.<sup>115</sup>

Wang *et al.*, employed two models of epileptic attacks: one based on 4-AP and used electrocorticography to confirm the



A



B

Fig. 15 (A) Percentage of IN subtypes recorded in EC slices obtained from GAD65 (and GAD67 mice). (B) Percentage of IN subtypes and PYRs recorded from superficial EC layers 2–3 and deep EC layers 4 and 5. For statistical analysis, Fisher's exact test with Bonferroni's correction was used.




Fig. 16 Structure of 3,4 diaminopyridine.

length of an epileptic episode (ECoG). TPM impacted neurovascular coupling in the area of epileptic activity, according to LSCI and ECoG data. TPM significantly reduced the gamma power in ECoG for 4-AP-induced epileptic seizures (4AP + TPM:  $0.61 \pm 0.13$  mV vs. 4-AP:  $1.08 \pm 0.19$  mV;  $p < 0.05$ ). Results confirmed that the instantaneous cortical LSCI and ECoG approach provided temporal and spatial information on the ictogenesis process and enabled the evaluation of pharmaceutical treatments' effectiveness in treating several types of epileptic seizures *in vivo* models (Fig. 14).<sup>116</sup>

Scalmani *et al.*, conducted recordings in patients with temporal lobe epilepsy and in models of temporal lobe seizures, demonstrating the activation of interneurons at the beginning of focal seizures. Specific interneuron (IN) subtypes were acknowledged as parvalbuminergic (INPV),  $n = 17$ , cholecystokinergic (INCK),  $n = 13$ , and somatostatinergic illogical characteristics. When 4AP-induced SLEs began, INPV and INCK discharged, and their onset patterns were hyper-synchronous. After the SLE, pyramidal neurons were active with varying delays. 50% of the cells in each IN subgroup showed depolarizing block, which lasted longer in iN (4s) than in pyramidal neurons (1s). All IN produced action potential bursts synchronized with the field potential trials that caused SLE termination as the condition progressed. These findings implied that IN played a predominant role in the onset and initiation of focal seizures and corroborate previous *in vivo* and *in vitro* data (Fig. 15A and B).<sup>117</sup>

### 2.13 Anti-botulism

Botulism is a severe paralytic disorder caused by a neurotoxin produced by *Clostridium botulinum*.<sup>118</sup> McClintic *et al.*, described aminopyridines for treatments of botulism caused by botulinum neurotoxin (BoNT) that is an effective protein causing muscle paralysis and death by asphyxiation. When given consistently to mouse models of deadly botulism, the licensed medication 3,4-DAP (**84**) promptly reverses toxic indications of botulism and has antidote benefits. The effects of 3,4-DAP **84** and other AP on respiratory and ventilation during the later stages of botulism in mice were examined using unrestrained whole-body plethysmography (UWBP) and arterial blood gas measurements in combination (Fig. 16). A number of aminopyridines have therapeutic efficacies that were either superior to or equal to those of 3,4-DAP. These included






Fig. 17 Evaluation of aminopyridine derivatives on ventilation. Structures of aminopyridines. 3,4-DAP is included for comparison.

Table 12 Summary of physicochemical properties<sup>120</sup>

Compounds	MW	log <i>P</i>	p <i>K</i> <sub>a</sub>
10	94.1	0.3	9.17
84a	98.1	0.3	nd
84b	124.1	-1.2	9.08
84c	130.1	0.4	5.12
84e	109.1	-0.2	9.14
84f	112.2	0.6	3.76
84g	109.1	-0.5	9.17
41a	112.1	0.3	7.19
41b	112.2	0.5	9.43

aminopyridines that specifically increased tidal volume *vs.* respiratory level and *vice versa* (Fig. 17 and Table 12).<sup>119</sup>

### 3 Conclusion

Aminopyridines have emerged as a highly multifaceted and exceptional class of molecules with a wide array of biological activities and therapeutic potentials *via* targeting various enzyme receptors and ion channels. The recent advances in their synthesis have displayed innovative methodologies that enhance efficiency, selectivity, and yield, making these compounds more convenient for research and pharmaceutical applications. The biological activities of aminopyridines span a broad spectrum, including antibacterial, antifungal, anti-inflammatory effects, antiviral, anticancer, anti-botulism, anti-epileptic agents, anti-tuberculosis, anti-tranquilizing, antidepressants, anti-neurodegenerative, anti-multiple sclerosis, antitrypanosomal and anti-malarial agents. These activities underscore their potential as lead compounds in drug discovery and development. Structure–activity relationship (SAR) studies

have been pivotal in understanding the mechanisms underlying these activities and have become significant for the rational design of more potent and selective aminopyridine derivatives. Key strategies, mainly transition metal-catalysed reactions, green chemistry approaches, and novel synthetic routes, have significantly contributed to the progress in this field. Despite the substantial progress, challenges remain, particularly in optimizing the pharmacokinetic and pharmacodynamics properties of aminopyridines to ensure their efficacy and safety in clinical profiles. Future research should focus on addressing these challenges, exploring novel synthetic methodologies, and expanding the scope of biological evaluations to fully harness the therapeutic potential of aminopyridines.

### Data availability

No primary research results, software or code have been included and no new data were generated or analysed as part of this review.

### Author contributions

T. Khalid: writing – review & editing. A. Malik: supervision, validation, and investigation. N. Rasool: validation, and investigation. A. Kanwal & H. Nawaz: review & editing. I. Almas: writing – review & editing.

### Conflicts of interest

There are no conflicts to declare.



## Acknowledgements

We strongly acknowledge the Organic material synthesis lab of Government College University, Faisalabad.

## References

- 1 S. Pearce, *Drug Discovery*, 2017, **67**, 1–5.
- 2 K. Schofield, *Hetero-aromatic Nitrogen Compounds: Pyrroles and Pyridines*, Springer, 2013.
- 3 M. B. Islam, M. I. Islam, N. Nath, T. B. Emran, M. R. Rahman, R. Sharma and M. M. Matin, *BioMed Res. Int.*, 2023, **2023**, 1–15.
- 4 F. Islam, M. A. Hossain, N. M. Shah, H. T. Barua, M. A. Kabir, M. J. Khan and R. Mullick, *J. Chem.*, 2015, **2015**, 1–8.
- 5 S. De, A. K. SK, S. K. Shah, S. Kazi, N. Sarkar, S. Banerjee and S. Dey, *RSC Adv.*, 2022, **12**, 15385–15406.
- 6 C. Verma, K. Y. Rhee, M. Quraishi and E. E. Ebenso, *J. Taiwan Inst. Chem. Eng.*, 2020, **117**, 265–277.
- 7 X. H. Makhoba, *Recent Developments in the Synthesis and Applications of Pyridines*, 2023, pp. 143–158.
- 8 S. R. Alizadeh and M. A. Ebrahimzadeh, *Mini Rev. Med. Chem.*, 2021, **21**, 2584–2611.
- 9 N. Siddiqui, W. Ahsan, M. S. Alam, B. Azad and M. J. Akhtar, *Res. J. Pharm. Technol.*, 2011, **4**, 1918–1932.
- 10 S. Cherukupalli, R. Karpoomath, B. Chandrasekaran, G. A. Hampannavar, N. Thapliyal and V. N. Palakollu, *Eur. J. Med. Chem.*, 2017, **126**, 298–352.
- 11 R. Sahu, R. Mishra, R. Kumar, C. Majee, A. Mazumder and A. Kumar, *Mini Rev. Med. Chem.*, 2022, **22**, 248–272.
- 12 M. Sankara and L. Sidde, *Int. J. Pharmacogn. Chem.*, 2020, 12–18.
- 13 A. Riedel, R. Lang, B. Rohm, M. Rubach, T. Hofmann and V. Somoza, *J. Nutr. Biochem.*, 2014, **25**, 750–757.
- 14 N. Shafiq, N. Shahzad, F. Rida, Z. Ahmad, H. A. Nazir, U. Arshad, G. Zareen, N. Attiq, S. Parveen and M. Rashid, *Future Med. Chem.*, 2023, **15**, 1069–1089.
- 15 P. Narendar, J. Parthiban, N. Anbalagan, V. Gunasekaran and J. T. Leonard, *Biol. Pharm. Bull.*, 2003, **26**, 182–187.
- 16 R. M. Mohareb, M. Y. Zaki and N. S. Abbas, *Steroids*, 2015, **98**, 80–91.
- 17 L. M. Potikha and V. S. Brovarets, *Chem. Heterocycl. Compd.*, 2020, **56**, 1460–1464.
- 18 Y. Ling, Z.-Y. Hao, D. Liang, C.-L. Zhang, Y.-F. Liu and Y. Wang, *Drug Des. Dev. Ther.*, 2021, 4289–4338.
- 19 S. Malynych, I. Luzinov and G. Chumanov, *J. Phys. Chem. B*, 2002, **106**, 1280–1285.
- 20 T. Chand and B. Savitri, *Ind. Biotechnol. Vitam., Biopigm., Antioxid.*, 2016, 41–65.
- 21 V. Gasperi, M. Sibilano, I. Savini and M. V. Catani, *Int. J. Mol. Sci.*, 2019, **20**, 974.
- 22 E. Anderson, *Drugs, Labor, and Colonial Expansion*, 2003, p. 159.
- 23 B. T. Green, S. T. Lee, K. E. Panter and D. R. Brown, *Food Chem. Toxicol.*, 2012, **50**, 2049–2055.
- 24 R. E. Dewey and J. Xie, *Phytochemistry*, 2013, **94**, 10–27.
- 25 S. Worbs, K. Köhler, D. Pauly, M.-A. Avondet, M. Schaer, M. B. Dorner and B. G. Dorner, *Toxins*, 2011, **3**, 1332–1372.
- 26 R. J. Bertz, A. Persson, E. Chung, L. Zhu, J. Zhang, D. McGrath and D. Grasela, *Pharmacotherapy*, 2013, **33**, 284–294.
- 27 Y. Chen, X. Dong, Q. Wang, Z. Liu, X. Dong, S. Shi and H. Xiao, *Front. Pharmacol.*, 2020, **11**, 569843.
- 28 C. A. Calderón-Ospina and M. O. Nava-Mesa, *CNS Neurosci. Ther.*, 2020, **26**, 5–13.
- 29 J. L. Griffin, S. A. Bonney, C. Mann, A. M. Hebbachi, G. F. Gibbons, J. K. Nicholson, C. C. Shoulders and J. Scott, *Physiol. Genomics*, 2004, **17**, 140–149.
- 30 R. N. Rao and K. Chanda, *Chem. Commun*, 2022, **58**, 343–382.
- 31 M. J. Dias Pires, D. L. Poeira and M. M. B. Marque, *Eur. J. Org Chem.*, 2015, **2015**, 7197–7234.
- 32 S. Ekins, J. Mestres and B. Testa, *Br. J. Pharmacol.*, 2007, **152**, 21–37.
- 33 S. Momeni and R. Ghorbani-Vaghei, *Sci. Rep.*, 2023, **13**, 1–12.
- 34 Q. Q. Lu, Y. M. Chen, H. R. Liu, J. Y. Yan, P. W. Cui, Q. F. Zhang, X. H. Gao, X. Feng and Y. Z. Liu, *Drug Dev. Res.*, 2020, **81**, 1037–1047.
- 35 L. Kang, X.-H. Gao, H.-R. Liu, X. Men, H.-N. Wu, P.-W. Cui, E. Oldfield and J.-Y. Yan, *Mol. Diversity*, 2018, **22**, 893–906.
- 36 J. Chen, D. Yang, Y. Zhang, L. Yang, Q. Wang, M. Jiang and L. Pan, *Int. J. Biol. Macromol.*, 2024, **259**, 1–15.
- 37 F. Fastier and M. McDowall, *Aust. J. Exp. Biol. Med. Sci.*, 1958, **36**, 365–372.
- 38 J. L. Segal, J. F. Thompson and J. A. Tayek, *Pharmacotherapy*, 2007, **27**, 789–792.
- 39 X. H. Gao, J. J. Tang, H. R. Liu, L. B. Liu and Y. Z. Liu, *Drug Dev. Res.*, 2019, **80**, 438–445.
- 40 A. M. King, N. B. Menke, K. D. Katz and A. F. Pizon, *J. Med. Toxicol.*, 2012, **8**, 314–321.
- 41 V. I. Leussink, X. Montalban and H.-P. Hartung, *CNS Drugs*, 2018, **32**, 637–651.
- 42 M. Malhotra, P. Ghai, B. Narasimhan and A. Deep, *Arab. J. Chem.*, 2016, **9**, S1443–S1449.
- 43 D. Moro-Sibilot, N. Cozic, M. Pérol, J. Mazières, J. Otto, P. Souquet, R. Bahleda, M. Wislez, G. Zalcman and S. Guibert, *Ann. Oncol.*, 2019, **30**, 1985–1991.
- 44 D. F. Heigener and M. Reck, *Small Molecules in Oncology*, 2018, pp. 57–65.
- 45 S. Lindquist and M. Stangel, *Neuropsychiatr. Dis. Treat.*, 2011, 341–349.
- 46 H. G. Piskorik, *Analytical profiles of drug substances, Elsevier*, 1985, **14**, 107–133.
- 47 C. P. Fitzsimons, F. Monczor, N. Fernández, C. Shayo and C. Davio, *J. Biol. Chem.*, 2004, **279**, 34431–34439.
- 48 K. K. Gaines, *Urol. Nurs.*, 2004, **24**, 207–209.
- 49 J. Hao, L. Brosse, C. Bonnet, M. Ducrocq, F. Padilla, V. Penalba, A. Desplat, J. Ruel and P. Delmas, *Faseb. J.*, 2021, **35**, e22025.
- 50 H. C. de Kraker, *The University of Texas at San Antonio*, 2022.
- 51 H. Li, C. Zhang, R. Fan, H. Sun, H. Xie, J. Luo, Y. Wang, H. Lv and T. Tang, *J. Ethnopharmacol.*, 2016, **193**, 117–124.



- 52 K. Jones, Five- and six-membered fused systems with bridgehead (ring junction) heteroatoms concluded : 6-6 bicyclic with one or two N or other heteroatoms, *Polycyclic, Spirocyclic*, Elsevier, 2008.
- 53 P. Bing, W. Zhou and S. Tan, *Front. Pharmacol*, 2022, **13**, 1–10.
- 54 L. E. Kass and J. Nguyen, *Wiley Interdiscip. Rev.:Nanomed. Nanobiotechnol.*, 2022, **14**, e1756.
- 55 L. Strękowski, Five- and six-membered fused systems with bridgehead (ring junction) heteroatoms including 6-6 bicyclic with one or two Nitrogen or other heteroatoms, *Polycyclic, Spirocyclic*, Elsevier, 2022.
- 56 M. Fioranelli, M. G. Rocca, D. Flavin and L. Cota, *Int. J. Mol. Sci.*, 2021, **22**, 5277.
- 57 E. R. Rayburn, S. J. Ezell and R. Zhang, *Mol. Cell. Pharmacol.*, 2009, **1**, 29.
- 58 M. Philip, D. A. Rowley and H. Schreiber, *Semin. Cancer Biol.*, 2004, 433–439.
- 59 N. Hfidhi, I. Bkhairia, D. Atoui, J. Boonmak, M. Nasri, R. Ben Salem, S. Youngme and H. Naili, *Appl. Organomet. Chem.*, 2019, **33**, e4793.
- 60 J. Williams-Nguyen, J. B. Sallach, S. Bartelt-Hunt, A. B. Boxall, L. M. Durso, J. E. McLain, R. S. Singer, D. D. Snow and J. L. Zilles, *J. Environ. Qual.*, 2016, **45**, 394–406.
- 61 M. A. Salam, M. Y. Al-Amin, M. T. Salam, J. S. Pawar, N. Akhter, A. A. Rabaan and M. A. Alqumber, *Healthcare*, 2023, 1946.
- 62 Z. Kibou, N. Aissaoui, I. Daoud, J. A. Seijas, M. P. Vázquez-Tato, N. Klouche Khelil and N. Choukchou-Braham, *Molecules*, 2022, **27**, 3439.
- 63 U. S. F. Arrozi and S. Sugiarto, *Indones. J. Chem.*, 2023, **23**, 1108–1119.
- 64 M. S. Al-Fakeh, M. A. Alsikhan and J. S. Alnawmasi, *Molecules*, 2023, **28**, 2555.
- 65 K. J. Orie, P. J. Nna and R. U. Duru, *Res. J. Pure Sci. Technol.*, 2024, **7**, 96–107.
- 66 H. İlkinen and A. GÜLBANDILAR, *Pamukkale UJ Eng. Sci.*, 2024, **1000**, 1–7.
- 67 M. De Rycker, S. Wyllie, D. Horn, K. D. Read and I. H. Gilbert, *Nat. Rev. Microbiol.*, 2023, **21**, 35–50.
- 68 P. Büscher, G. Cecchi, V. Jamonneau and G. Priotto, *Lancet*, 2017, **390**, 2397–2409.
- 69 C. G. Veale, D. Laming, T. Swart, K. Chibale and H. C. Hoppe, *ChemMedChem*, 2019, **14**, 2034–2041.
- 70 R. Silva-Oliveira, L. S. Sangenito, A. Reddy, T. Velasco-Torrijos, A. L. Santos and M. H. Branquinha, *Trop. Med. Infect. Dis.*, 2023, **8**, 1–15.
- 71 A. J. Thompson, B. L. Banwell, F. Barkhof, W. M. Carroll, T. Coetzee, G. Comi, J. Correale, F. Fazekas, M. Filippi and M. S. Freedman, *Lancet Neurol.*, 2018, **17**, 162–173.
- 72 C. Walton, R. King, L. Rechtman, W. Kaye, E. Leray, R. A. Marrie, N. Robertson, N. La Rocca, B. Uitdehaag and I. van Der Mei, *Mult. Scler. J.*, 2020, **26**, 1816–1821.
- 73 C. Bevan and J. M. Gelfand, *Curr. Treat. Options Neurol.*, 2015, **17**, 1–14.
- 74 S. Rodríguez-Rangel, A. D. Bravin, K. M. Ramos-Torres, P. Brugarolas and J. E. Sánchez-Rodríguez, *Sci. Rep.*, 2020, **10**, 52.
- 75 E. C. Aydoğmuş and G. I. Garip, *Cancer Rep.*, 2024, **7**, e70072.
- 76 R. Abbas, H. Inayah, H. Hassan and F. F. Al-Kazzaz, *Medico-Legal Update*, 2021, 21.
- 77 M. Dietrich, H.-P. Hartung and P. Albrecht, *Neurol. Neuroimmunol. Neuroinflamm.*, 2021, **8**, e976.
- 78 F. Türker, S. A. A. Noma, A. Aktaş, K. Al-Khafaji, T. Taşkın Tok, B. Ateş and Y. Gök, *Monatsh. fur Chem.*, 2020, **151**, 1557–1567.
- 79 A. Shakeel, A. A. Altaf, A. M. Qureshi and A. Badshah, *J. Drug Des. Med. Chem.*, 2016, **2**, 1–12.
- 80 F. Rizvi, R. Ahmed, M. A. Bashir, S. Ullah, H. Zafar, A. tu-Wahab, H. Siddiqui and M. I. Choudhary, *Future Med. Chem.*, 2023, **15**, 1757–1772.
- 81 D. R. Niri, M. H. Sayahi, S. Behrouz, A. Moazzam, F. Rasekh, N. Tanideh, C. Irajie, M. S. Nezhad, B. Larijani and A. Irajii, *Heliyon*, 2023, **9**, 1–11.
- 82 M. Sopjani, R. Morina, V. Uka, N. T. Xuan and M. Dërmaku-Sopjani, *Curr. Mol. Med.*, 2021, **21**, 417–425.
- 83 W. Wang, Y. Diao, W. Li, Y. Luo, T. Yang, Y. Zhao, T. Qi, F. Xu, X. Ma and H. Ge, *Bioorg. Med. Chem. Lett.*, 2019, **29**, 1507–1513.
- 84 N. Munir, T. A. Chohan, A. Qayyum, T. A. Chohan, F. Batool, M. W. Mustafa, S. Anwar, F. Alheibshy, W. Hussein and A. Alafnan, *J. Biomol. Struct. Dyn.*, 2024, 1–16.
- 85 H. Fu, J. Hardy and K. E. Duff, *Nat. Neurosci.*, 2018, **21**, 1350–1358.
- 86 M. Noble, K.-C. Tseng, H. Li and J. C. Elfar, *Mil. Med.*, 2019, **184**, 379–385.
- 87 L. Yue, M. Talukder, A. Gurjar, J. I. Lee, M. Noble, R. T. Dirksen, J. Chakkalakal and J. C. Elfar, *Muscle Nerve*, 2019, **60**, 192–201.
- 88 D. Vasu, H. T. Do, H. Li, C. D. Hardy, A. Awasthi, T. L. Poulos and R. B. Silverman, *J. Med. Chem.*, 2023, **66**, 9934–9953.
- 89 P. C. Götzsche and O. Dinnage, *Int. J. Risk Saf. Med.*, 2020, **31**, 157–163.
- 90 S. Kloiber and G. Konstantinou, in *NeuroPsychopharmacotherapy*, Springer, 2022, pp. 2037–2051.
- 91 B. Costall, B. Jones, M. Kelly, R. Naylor and D. Tomkins, *Pharmacol. Biochem. Behav.*, 1989, **32**, 777–785.
- 92 I. V. Palamarchuk, Z. T. Shulgau, M. A. Kharitonova and I. V. Kulakov, *Chem. Pap.*, 2021, **75**, 4729–4739.
- 93 G. A. C. Blood, *Transfus. Med. Hemotherapy*, 2016, **43**, 203.
- 94 I. Palamarchuk, Z. Shulgau, S. D. Sergazy, A. Zhulikeeva, T. Seilkanov and I. Kulakov, *Russ. J. Gen. Chem.*, 2022, **92**, 1692–1705.
- 95 P. K. Govindappa, M. Jagadeeshaprasad, M. Talukder and J. Elfar, *FASEB J.*, 2021, **35**, 1–14.
- 96 T. Parmentier, F. M. James, E. Hewitson, C. Bailey, N. Werry, S. D. Sheridan, R. H. Perlis, M. L. Perreault, L. Gaitero and J. Lalonde, *Sci. Rep.*, 2022, **12**, 9143.



## Review

- 97 L. Shi, L. Jia, Y. Wang, M. Xiu and J. Xie, *Neurochem. Res.*, 2023, **48**, 1707–1715.
- 98 Y. Sun, N. J. Guehl, Y.-P. Zhou, K. Takahashi, V. Belov, M. Dhaynaut, S.-H. Moon, G. El Fakhri, M. D. Normandin and P. Brugarolas, *ACS Chem. Neurosci.*, 2022, **13**, 3342–3351.
- 99 D. Paul, *J. Cancer Metastasis Treat.*, 2020, **6**, 1–31.
- 100 C.-H. Jiang, T.-L. Sun, D.-X. Xiang, S.-S. Wei and W.-Q. Li, *Front. Pharmacol.*, 2018, **9**, 1–13.
- 101 F. Bray, M. Laversanne, E. Weiderpass and I. Soerjomataram, *Cancer*, 2021, **127**, 3029–3030.
- 102 Z. Guo, K. Guan, M. Bao, B. He and J. Lu, *Pathol., Res. Pract.*, 2024, **260**, 155460.
- 103 M. Sadia, J. Khan, R. Naz, M. Zahoor, S. W. A. Shah, R. Ullah, S. Naz, A. Bari, H. M. Mahmood and S. S. Ali, *J. King Saud Univ., Sci.*, 2021, **33**, 101331.
- 104 S. Naz, F. A. Shah, H. Nadeem, S. Sarwar, Z. Tan, M. Imran, T. Ali, J. B. Li and S. Li, *Drug Des., Dev. Ther.*, 2021, 1459–1476.
- 105 Y. Y. Yan, X. X. Zhang, Y. Xiao, X. B. Shen, Y. J. Jian, Y. M. Wang, Z. H. She, M. M. Liu and X. H. Liu, *J. Med. Chem.*, 2022, **65**, 13216–13239.
- 106 K. Hchicha, M. Korb, R. Badraoui and H. Naïli, *New J. Chem.*, 2021, **45**, 13775–13784.
- 107 R. Teran, R. Guevara, J. Mora, L. Dobronski, O. Barreiro-Costa, T. Beske, J. Pérez-Barrera, R. Araya-Maturana, P. Rojas-Silva and A. Poveda, *Molecules*, 2019, **24**, 1–20.
- 108 N. Mhadhbi, N. Issaoui, W. S. Hamadou, J. M. Alam, A. S. Elhadi, M. Adnan, H. Naïli and R. Badraoui, *ChemistrySelect*, 2022, **7**, 1–9.
- 109 W. Luan, M. Zheng, Y. Yang, Y. Chen, X. Zhang, L. Zhu and C. Lin, *Gold Bull.*, 2023, 1–12.
- 110 S. Liu, C. Huang, C. Huang, Y. Huang, Y. Yu, G. Wu, F. Guo, Y. Jiang, S. Wan and Z. Zhu, *J. Enzyme Inhib. Med. Chem.*, 2023, **38**, 2227779.
- 111 H. Li, Y. Wang, R. Fan, H. Lv, H. Sun, H. Xie, T. Tang, J. Luo and Z. Xia, *Drug Des., Dev. Ther.*, 2016, 2173–2180.
- 112 S. B. Lagu, R. P. Yejella, S. Nissankararao, R. R. Bhandare, V. S. Golla, B. V. Subrahmanya Lokesh, M. M. Rahman and A. B. Shaik, *PLoS One*, 2022, **17**, 1–12.
- 113 S. Balestrini, A. Arzimanoglou, I. Blümcke, I. E. Scheffer, S. Wiebe, J. Zelano and M. C. Walker, *Epileptic Disord.*, 2021, **23**, 1–16.
- 114 B. Villasana-Salazar, R. Hernández-Soto, M. E. Guerrero-Gómez, B. Ordaz, G. Manrique-Maldonado, K. Salgado-Puga and F. Peña-Ortega, *Epilepsy Res.*, 2020, **166**, 106375.
- 115 U. B. Hedrich, S. Lauxmann, M. Wolff, M. Synofzik, T. Bast, A. Binelli, J. M. Serratosa, P. Martínez-Ulloa, N. M. Allen and M. D. King, *Sci. Transl. Med.*, 2021, **13**, eaaz4957.
- 116 Y. Wang, V. Tsytsarev and L.-D. Liao, *APL Bioeng.*, 2023, **7**, 1–14.
- 117 P. Scalmani, R. Paterra, M. Mantegazza, M. Avoli and M. de Curtis, *J. Neurosci.*, 2023, **43**, 1987–2001.
- 118 Z. F. Dembek, L. A. Smith and J. M. Rusnak, *Disaster Med. Public Health Prep.*, 2007, **1**, 122–134.
- 119 W. T. McClintic, Z. D. Chandler, L. M. Karchalla, C. A. Ondeck, S. W. O'Brien, C. J. Campbell, A. R. Jacobson and P. M. McNutt, *J. Pharmacol. Exp. Ther.*, 2024, **388**, 637–646.
- 120 W. T. McClintic, Z. D. Chandler, S. W. O'Brien, A. Jacobson and P. M. McNutt, *Toxicol.*, 2024, **237**, 107456.

